RAPS announces Board of Directors slate for 2025
RAPS today announced its Board of Directors for 2025 following careful review of all nominations for two open Director positions and the position of Board President.
“These regulatory professionals are inspiring in their dedication to service and leadership,” RAPS Nominating Committee Chair Glenn Byrd said. “We are confident they have the experience and commitment necessary to lead the regulatory profession well into the future.”
On behalf of RAPS and the RAPS Nominating Committee, the new members of the RAPS Board of Directors are presented below. They will begin their terms on 1 January 2025.
Chair
-
Jethro Ekuta, DVM, PhD, RAC, FRAPS, Vice President, Global Regulatory Affairs at Alexion Pharmaceuticals
Ekuta, currently President of the Board, will succeed Gert Bos, who currently serves as Board Chair.
President
-
Diana Salditt, FRAPS, Principal Consultant at Salditt Regulatory Consulting
Salditt currently serves as a Director, and her term as Director will expire on 31 December 2024.
Directors
-
Megha D. Iyer, MS, RAC, FRAPS, Director, Global Strategic Regulatory Affairs at Thermo Fisher Scientific
-
Mindy McCann, FRAPS, VP US Operations and Principal Consultant, QServe Group USA
RAPS would like to thank the following outgoing members of the Board of Directors for their service to RAPS and commitment to supporting the regulatory community. These directors will reach the end of their terms on the board on 31 December 2024.
-
Gert Bos, PhD, FRAPS, Chair
-
Carol Cooper, MS, IM(ASCP), RM(AAM), RAC, Director
About the RAPS Board of Directors
The RAPS Board of Directors is the governing, policy-making and strategic body that guides RAPS in serving the regulatory professional and the regulatory profession around the world. Learn more about the RAPS Board of Directors and the role it plays in serving RAPS and the global regulatory profession. Inquiries about the nominations process for the RAPS Board of Directors can be emailed to [email protected].